Journal: Cancer Science

Article Title: Synthetic disulfide-bridged cyclic peptides mimic the anti-angiogenic actions of chondromodulin-I

doi: 10.1111/j.1349-7006.2012.02276.x

Figure Lengend Snippet: Effects of the synthetic and tailed chondromodulin-I (ChM-I) cyclic peptide on tumor angiogenesis and growth in an animal model in which OUMS-27 cells (5 × 10 6 cells) were subcutaneously inoculated in the backs of 4 week-old nude mice. (A) Time-course of tumor volume changes. When the tumor volume reached about 45 mm 3 , each mouse was injected around the tumor mass each day for the initial 5 days with PBS (50 μL) alone (♢), PBS containing 4.3 nmol (20 μg) ChM-I cyclic peptide with a tail (○), or PBS containing 0.2 nmol (5 μg) recombinant human ChM-I (rhChM-I) (●) (arrows). The tumor volumes were determined by the width 2 × length × 0.52. Values are the means ± SD from at least six animals per group. (B) Gross appearance of tumors excised on day 21. Bar, 10 mm. (C) Immunohistochemical staining of the CD31-positive vasculature. On day 21, tumor tissues were excised, fixed, and cross-sectioned. The sections were then stained with toluidine blue (left panels), and semi-serial sections were stained with an anti-type II collagen antibody ( green signal in the right panels) and an anti-CD31 antibody ( red signal in the right panels), respectively. Bars, 100 μm. (D) The CD31-positive area was measured as described in the methods section. Values are the means ± SD of five tumors per group. * P < 0.05, ** P < 0.01.

Article Snippet: Anti-CD31 antibody and anti-collagen type II antibody were obtained from BD PharMingen (San Diego, CA, USA) and Rockland (Gilvertsville, PA, USA), respectively.

Techniques: Animal Model, Injection, Recombinant, Immunohistochemical staining, Staining

Journal: Materials Today Bio

Article Title: Delivered baicalein immunomodulatory hydrogel with dual properties of pH-responsive and anti-infection orchestrates pro-regenerative response of macrophages for enhanced hypertrophic scars therapy

doi: 10.1016/j.mtbio.2025.102160

Figure Lengend Snippet: Functional performance and biocompatibility evaluation of hydrogels. (A) Photographs of MRSA and E.coil colonies, and (B, C) corresponding quantitative calculation of antibacterial rates after treatments of different hydrogels. (D) Representative scratch assay images of L929 cells treated with different hydrogels and (E) corresponding quantitative analysis of cell migration rates based on scratch area. ELISA was performed to assess the expression of CD31 (F) and VEGF (G) in HUVEC cells following treatment with various hydrogels. (H) Photographs of hemolysis assays and (I) statistically analyzed hemolysis rates. (J) Cytocompatibility of hydrogels and in vivo hematological parameters, including (K)white blood cell (WBC) count -, (L)red blood cell (RBC) count , and (M)platelet count. n = 3, ∗P < 0.05, ∗∗P < 0.01 and ∗∗∗P < 0.001. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

Article Snippet: Following seeding in 12-well culture plates, HUVECs were maintained for 72 h in experimental media supplemented with different test materials, after which the supernatants were collected, centrifuged, and analyzed for CD31 (E-EL-H6227, Elabscience) and VEGF (E-EL-H0111, Elabscience) concentrations.

Techniques: Functional Assay, Wound Healing Assay, Migration, Enzyme-linked Immunosorbent Assay, Expressing, In Vivo